Safety and effectiveness of empagliflozin and linagliptin fixed-dose combination therapy in Japanese patients with type 2 diabetes: final results of a one-year post-marketing surveillance study-Reference-Cited by-同舟云学术

Safety and effectiveness of empagliflozin and linagliptin fixed-dose combination therapy in Japanese patients with type 2 diabetes: final results of a one-year post-marketing surveillance study

Published:2022-08-16 Issue:2 Volume:22 Page:153-163
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Inagaki Nobuya¹^ORCID,Nishimoto Takaaki²^ORCID,Nishiya Yoichi³^ORCID,Nitta Daisuke³^ORCID

Affiliation:

1. Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan

2. Medicines Development Unit Japan and Medical Affairs, Eli Lilly Japan K.K, Kobe, Japan

3. Medicine Division, Nippon Boehringer Ingelheim Co. Ltd, Tokyo, Japan

Funder

Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2022.2107200

Reference44 articles.

1. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045

2. Ministry of Health Labour and Welfare. The National Health and Nutrition Survey in Japan 2016.

3. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors

4. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Empagliflozin/linagliptin;Reactions Weekly;2023-06-17